Brazil Neurology Devices Market Summary 2025

Market Size in 2024: USD 244.8 million
Market Forecast in 2033: USD 375.8 million
Market Growth Rate 2025-2033: 4.38%

Brazil’s neurology-device sector is on a measured upward trajectory. After reaching USD 244.8 million in 2024, the Brazil neurology devices market is projected to climb to USD 375.8 million by 2033, reflecting a compound annual growth rate of 4.38% as stroke volumes rise, universal coverage expands, and minimally invasive technologies gain hospital adoption.

Growth Drivers Powering the Brazil Neurology Devices Market

SUS Expands Stroke-Care Reimbursement to 420 Tertiary Centres, Creating Device Pipeline

Brazil’s Unified Health System (SUS) added mechanical thrombectomy to its approved procedures list in January 2025, extending reimbursement to 420 accredited tertiary hospitals. The Ministry of Health allocated BRL 480 million for 2025-26 to cover devices such as stent-retrievers and aspiration catheters, with a guaranteed payment of BRL 28,000 per case. Because SUS now funds up to 75% of the device cost, private hospitals are aligning procurement with public tariffs, effectively enlarging the addressable market for suppliers. Early adopters in São Paulo report a 32% increase in stroke interventions within six months, validating volume growth that underpins the forecast CAGR.

Neurostimulation Reimbursement Ceiling Raised 18%, Accelerating DBS Uptake

The National Supplementary Health Agency (ANS) raised the reimbursement ceiling for deep-brain stimulation (DBS) by 18% in March 2025, matching the average private-hospital invoice of BRL 135 000. Because insurers must cover the procedure within 21 days of request, waiting lists for Parkinson’s and epilepsy patients have shortened from eight to three months. Hospitals are responding by upgrading hybrid operating rooms: Hospital Sírio-Libanês installed a fourth intra-operative MRI suite in April 2025, citing DBS volume as the primary driver. The shorter reimbursement cycle removes a major cost barrier, encouraging more centres to offer neurostimulation and locking in recurring electrode-replacement revenue for manufacturers.

Local Production Incentives Cut Import Duty to 2%, Encouraging OEM Assembly

The Reintegra programme, renewed in January 2025, grants a 3% tax credit on export revenue for medical-device manufacturers that assemble at least 60% of the bill of materials in Brazil. Import duty on neuro-interventional catheters drops from 14% to 2% under the scheme, while states such as Minas Gerais add a further ICMS reduction to 4%. Medtronic’s facility in Suzano began final assembly of neurothrombectomy catheters in June 2025, targeting 200,000 units annually for Mercosur. Because landed cost falls 8-10%, distributors can price competitively against Asian imports, expanding hospital adoption outside tier-one cities and supporting mid-single-digit revenue growth through the decade.

Request a Free Sample Report to Access Full Data: https://www.imarcgroup.com/brazil-neurology-devices-market/requestsample

Brazil Neurology Devices Market Segmentation

Analysis by Device Type

• Cerebrospinal Fluid Management Devices
• Interventional Neurology Devices
  • Interventional/Surgical Simulators
  • Neurothrombectomy Devices
  • Carotid Artery Stents
  • Embolic Coils
  • Support Devices
• Neurosurgery Devices
  • Neuroendoscopes
  • Stereotactic Systems
  • Aneurysm Clips
  • Others
• Neurostimulation Devices
  • Spinal Cord Stimulation Devices
  • Deep Brain Stimulation Devices
  • Sacral Nerve Stimulation Devices
  • Others
• Others

Analysis by Region

• Southeast
• South
• Northeast
• North
• Central-West

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Brazil Neurology Devices Market News

• June 2025 – Medtronic’s Suzano plant began final assembly of neurothrombectomy catheters, targeting 200,000 units annually under the Reintegra tax-credit scheme.
• March 2025 – ANS raised DBS reimbursement by 18%, cutting patient waiting lists from eight to three months and driving hybrid-OR upgrades.
• January 2025 – SUS added mechanical thrombectomy to its approved list, allocating BRL 480 million and extending coverage to 420 tertiary centres.
• November 2024 – Hospital Sírio-Libanês opened a fourth intra-operative MRI suite, citing increased DBS volume as the primary driver.

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.